FindTrial
Sign In

Genexol-PM

DRUG5 trials

Sponsors

Samyang Biopharmaceuticals Corporation, National Cancer Center, Korea, Gachon University Gil Medical Center

Conditions

Breast CancerCarcinoma, HepatocellularGynecologic CancerMetastatic Adenocarcinoma of the PancreasPancreatic CancerRecurrent Adenocarcinoma of the Pancreas

Phase 1

Trial to Determine the Maximum Tolerated Dose of Genexol-PM Plus Gemcitabine and Evaluate Efficacy and Safety of Genexol-PM Regimens in Subjects With Advanced Pancreatic Cancer
CompletedNCT00882973
Samyang Biopharmaceuticals CorporationPancreatic Cancer
Start: 2008-09-30End: 2010-11-30Updated: 2017-05-05
Study to Evaluate the Efficacy and Safety of Genexol-PM Once a Week for Gynecologic Cancer
NCT02739529
Samyang Biopharmaceuticals CorporationGynecologic Cancer
Start: 2016-04-30End: 2018-03-31Target: 18Updated: 2017-05-01

Phase 2

Genexol-PM Versus Paclitaxel in Anthracycline-pretreated Metastatic Breast Cancer Patients
WithdrawnNCT01169870
National Cancer Center, KoreaBreast Cancer
Start: 2007-07-31End: 2008-10-31Updated: 2012-01-04
Study of Weekly Genexol®-PM Plus Gemcitabine in Subjects With Recurrent and Metastatic Adenocarcinoma of the Pancreas
NCT02739633
Samyang Biopharmaceuticals CorporationMetastatic Adenocarcinoma of the Pancreas, Recurrent Adenocarcinoma of the Pancreas
Start: 2016-04-30End: 2019-12-31Target: 47Updated: 2018-04-18
A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib
TerminatedNCT03008512
Gachon University Gil Medical CenterCarcinoma, Hepatocellular
Start: 2016-10-31End: 2021-02-28Updated: 2021-02-04

Related Papers

Phase 2 study of weekly polymeric micelle-formulated paclitaxel plus gemcitabine in patients with recurrent and metastatic adenocarcinoma of the pancreas.
Journal of Clinical Oncology2023-06-016 citations